Expanded Access Program of Ponatinib
Public ClinicalTrials.gov record NCT01592136. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Expanded Access Program of Ponatinib (AP24534) for Patients With Refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This protocol will allow expanded access of ponatinib to patients ≥18 years with chronic myeloid leukemia (CML) any phase or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) who have failed all available treatment options.
Study identification
- NCT ID
- NCT01592136
- Recruitment status
- Approved For Marketing
- Study type
- Expanded access
- Phase
- Not listed
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Feb 6, 2018
United States locations
- U.S. sites
- 33
- U.S. states
- 23
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Moores UCSD Cancer Center, Site #165 | La Jolla | California | 92093 | — |
| Southern California Permanente Medical Group, Site #161 | San Marcos | California | 92069 | — |
| Kaiser Permanente Medical Center, Site #158 | Vallejo | California | 94589 | — |
| Smilow Cancer Hospital at Yale New Haven, Site #182 | New Haven | Connecticut | 06510 | — |
| Cancer Institute of Florida, Site #187 | Altamonte Springs | Florida | 32792 | — |
| H. Lee Moffitt Cancer Center & Research Institute, Site #017 | Tampa | Florida | 33612 | — |
| Emory University, Site # 058 | Atlanta | Georgia | 30322 | — |
| University of Chicago Medical Center, Site #001 | Chicago | Illinois | 60637 | — |
| Indiana Blood and Marrow Transplantation, Site #138 | Indianapolis | Indiana | 46237 | — |
| Norton Cancer Institute, Site #142 | Louisville | Kentucky | 40202 | — |
| University of Maryland, Site #040 | Baltimore | Maryland | 21201 | — |
| Tufts Medical Center, Site #141 | Boston | Massachusetts | 02111 | — |
| Dana-Farber Cancer Institute, Site 008 | Boston | Massachusetts | 02215 | — |
| University of Massachusetts Worcester, Site #152 | Worcester | Massachusetts | 01655 | — |
| University of Michigan Health System, Site #011 | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute, Site #034 | Detroit | Michigan | 48201 | — |
| Mayo Clinic, Site #044 | Rochester | Minnesota | 55905 | — |
| Freeman Cancer Institute, Site #190 | Joplin | Missouri | 64804 | — |
| Washington University School of Medicine, Site 007 | St Louis | Missouri | 63110 | — |
| John Theurer Cancer Center at Hackensack University Medical Center, Site 128 | Hackensack | New Jersey | 07601 | — |
| Roswell Park Cancer Institute, Site #029 | Buffalo | New York | 14263 | — |
| Weill Cornell Medical College - New York Presbyterian Hospital, Site #006 | New York | New York | 10065 | — |
| University of Rochester, Site 137 | Rochester | New York | 14627 | — |
| Duke University Medical Center, Site 003 | Durham | North Carolina | 27710 | — |
| Jewish Hospital, Site #175 | Cincinnati | Ohio | 45236 | — |
| Oregon Health & Science University (OHSU), Site 048 | Portland | Oregon | 97239 | — |
| Hospital of the University of Pennsylvania, Site #013 | Philadelphia | Pennsylvania | 19104 | — |
| Jeanes Hospital of TUHS, Site #127 | Philadelphia | Pennsylvania | 19111 | — |
| Medical University of South Carolina, Site #148 | Charleston | South Carolina | 29425 | — |
| Tennesse Oncology, PLLC, Site # 076 | Nashville | Tennessee | 37203 | — |
| The University of Texas M.D. Anderson Cancer Center, Site #005 | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute at the University of Utah, Site #043 | Salt Lake City | Utah | 84112 | — |
| Seattle Cancer Care Alliance, Site #100 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01592136, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 6, 2018 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01592136 live on ClinicalTrials.gov.